Feature | December 31, 2013

Boston Scientific Gains European Approval of Quadripolar CRT-Ds

Boston scientific autogen x4 crt-d crt ICD heart failure cardiac
December 31, 2013 — Boston Scientific Corp. has received CE mark approval of its X4 line of quadripolar cardiac resynchronization therapy defibrillator (CRT-D) systems, including the AutoGen X4, DynaGen X4 and InoGen X4 CRT-Ds, a suite of Acuity X4 quadripolar LV leads and the Acuity Pro lead delivery system. The company's latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient care and improve the implant experience.
 
Antonio Curnis, professor, head of electrophysiology, Brescia University, Civili Hospital, Brescia, Italy, and Dr. Luca Bontempi, an electrophysiologist in the same unit, performed one of the first implants of the AutoGen X4 CRT-Ds.
 
"The unique design of the Acuity X4 lead allows me to pace from more optimal locations while enabling excellent stability of the lead, low battery consumption and avoiding phrenic nerve stimulation, which are all important issues for CRT patients," said Curnis. "Thanks to the 17 pacing vector options, it is possible to manage microdislodgments of the lead and optimize pacing threshold without additional procedures, drastically reducing the risk to patients. This, along with Boston Scientific's outstanding battery technology, delivers a CRT-D system that truly benefits patients over the long term."
 
The Acuity X4 suite of quadripolar LV leads are designed with multiple electrode spacing configurations to accommodate individual patient anatomy, including 3-D spiral designs to maximize electrode contact with the myocardium and minimize pacing capture thresholds in non-apical locations. These leads also feature multiple fixation options to optimize stability and the industry's smallest lead tip to enable physicians to access vessels unavailable to other quadripolar leads.
 
The X4 line of quadripolar CRT-Ds offers the largest number of pacing vector options in the industry and helps physicians effectively address high-pacing capture thresholds and phrenic nerve stimulation, a common complication of CRT therapy due to close proximity of the phrenic nerve to the desired pacing location in the left ventricle. The X4 CRT-Ds also feature Boston Scientific's longevity and six-year warranty. An independent, single-center, observational study of 646 CRT-D recipients (n = 173 BSX, 416 MDT, 57 SJM devices) implanted between Jan. 1, 2008 and Dec. 31, 2010 recently published in the United States showed that during 2.7 +/- 1.5 years follow-up, only 4 percent of Boston Scientific device batteries had depleted, compared to 7 percent from St. Jude Medical and 25 percent from Medtronic [i]. X4 CRT-Ds utilize the same battery capacity and chemistry as the Boston Scientific devices used in this study.
 
Following CE mark approval of the X4 quadripolar CRT-D systems, Boston Scientific plans to initiate a global clinical trial to gather additional data on Acuity X4 leads in patients indicated for a CRT-D. This prospective, non-randomized observational study, Maximizing CRT Delivery by using multipolar coronary sinus lead family Acuity X4 (Rally X4), is expected to enroll up to 1,000 patients who will receive the Acuity X4 leads at approximately 100 centers across 18 countries.
 
Boston Scientific's X4 quadripolar CRT-D system is currently approved for use in CE mark countries only. In the United States, the X4 quadripolar CRT-D system is an investigational device and not available for sale.
 
For more information: www.bostonscientific.com
 
References
[i] Mian Bilal Alam, Muhammad Bilal Munir, Rohit Rattan, Susan Flanigan, Evan Adelstein, Sandeep Jain, and Samir Saba, Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators, Europace 2013 : eut301v1-eut301.

Related Content

cardiac rehab, cardiac rehabilitation, CHF, heart failure

Congestive heart failure patient Dorothy Moore committed herself to cardiac rehabilitation and increasing the amount of exercise she did and was able to reverse her heart failure class. Patient engagement is key to improving CHF patient quality of life and outcomes without the use of drugs and devices.

Feature | Cardiac Rehabilitation| May 24, 2016 | Karen D. Walker, RN, MSN, and Stephanie Rejc, MS
Cardiac rehabilitation and exercise training has been shown to improve clinical status and outcomes in congestive hea
Boston Scientific, FDA, IntelliNav XP ablation catheters, Rhythmia Mapping System

Rhythmia Mapping System image courtesy of Boston Scientific

Technology | Ablation Systems| May 23, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with...
News | Heart Failure| May 23, 2016
May 23, 2016 — In a guideline update published last week, the American College of Cardiology, American Heart Associat
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
News | Atrial Fibrillation| May 19, 2016
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision...
Bioventrix, Revivent-TC System, heart failure, first-in-man procedure
News | Heart Failure| May 19, 2016
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based...
Johns Hopkins, virtual heart modeling tool, VARP, arrhythmias, implanted defibrillator

Examples of how the computer model would classify one patient at high risk for heart arrhythmia and another at low risk. Image courtesy of Royc Faddis/Johns Hopkins University.

News | Cardiac Diagnostics| May 17, 2016
May 17, 2016 — An interdisciplinary Johns Hopkins University team has developed a...
News | Heart Failure| May 16, 2016
May 16, 2016 –To work towards a better method of diagnosis and treatment of...
News | Stem Cell Therapies| May 16, 2016
May 16,  2016 — Patients treated with processed autologous adipose-derived regenerative cells (ADRCs) injected into t
News | Ablation Systems| May 11, 2016
Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are...
Overlay Init